The Role of Whole-Body FDG PET/CT, Tc 99m MDP Bone Scintigraphy, and Serum Alkaline Phosphatase in Detecting Bone Metastasis in Patients with Newly Diagnosed Lung Cancer
Open Access
- 1 January 2009
- journal article
- research article
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 24 (2), 275-280
- https://doi.org/10.3346/jkms.2009.24.2.275
Abstract
Bone scan (BS) and serum alkaline phosphatase (ALP) concentration are used to detect bone metastasis in malignancy, although whole-body fluoro-D-glucose positron emission tomography computed tomography (FDG PET/CT) is being used increasingly. But BS is still used for the detection of metastatic bone lesion. So we compared the usefulness of PET/CT, BS, and serum ALP in detecting bone metastases in patients with newly diagnosed lung cancer. The medical record database was queried to identify all patients with a new diagnosis of lung cancer between January 2004 and December 2005, who had a PET/CT, BS, and serum ALP before treatment. We retrospectively reviewed all patients' records and radiological reports. One hundred eighty-two patients met the inclusion criteria. Bone metastases were confirmed in 30 patients. The sensitivity values were 93.3% for PET/CT, 93.3% for BS, 26.7% for serum ALP concentration, and 26.7% for BS complemented with serum ALP concentration. The respective specificity values were 94.1%, 44.1%, 94.1%, and 97.3%. The kappa statistic suggested a poor agreement among the three modalities. FDG PET/CT and BS had similar sensitivity, but PET/CT had better specificity and accuracy than BS. PET/CT is more useful than BS for evaluating bone metastasis. However, in the advanced stage, because of its high specificity, BS complemented with serum ALP is a cost-effective modality to avoid having to use PET/CT.Keywords
This publication has 23 references indexed in Scilit:
- The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.2006
- Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.2004
- Diagnosis of Occult Bone Metastases: Positron Emission TomographyPublished by Ovid Technologies (Wolters Kluwer Health) ,2003
- Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.2003
- Noninvasive Staging of Non-small Cell Lung Cancer*Chest, 2003
- PET Diagnostic Accuracy: Improvement with In-Line PET-CT System: Initial ResultsRadiology, 2002
- Usefulness of bone markers for detection of bone metastases in lung cancer patientsClinical Biochemistry, 2002
- Comparing whole body 18 F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.2001
- Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography.2001